AIM: To investigate the therapeutic effect and safety of ranibizumab and conbercept on macular edema secondary to non-ischemic retinal vein occlusion.

METHODS: Totally 80 cases(80 macular edema eyes)with macular edema secondary to non-ischemic retinal vein occlusion patients enrolled into our hospital from March 2014 to May 2018 were collected into our study and randomly divided into the group A(40 cases)and the group B(40 cases). The patients in the group A and group B underwent ranibizumab and conbercept intravitreal injections, respectively. The intraocular pressure, central macular thickness(CMT), best corrected visual acuity(BCVA)and central macular volume(CMV), the number of injections and the occurrence of ocular complications before and after treatment of 2 groups were recorded and compared.

RESULTS: After treatment 2wk to 3mo, compared with the group A, the CMT, BCVA, CMV and the cases of intravitreal injections had decreased(P<0.05), meanwhile the visual acuity had increased in the group B(65% vs 38%, P<0.05), however, there was no significant difference in the incidence of complications between the two groups(5% vs 0%, P=0.999).

CONCLUSION: Compared with the ranibizumab, the conbercept has advantage in treatment of macular edema secondary to non-ischemic retinal vein occlusion by improving the visual acuity, reducing the CMT, CMV and the times of intravitreal injections.